Fluoxetine

Introduction Overview

Generic Name

Fluoxetine

Brand Name

Prozac, Sarafem, Rapiflux, Selfemra

Dosage Form

Oral delayed-release capsules, oral capsules, oral solution

Drug Class

Selective serotonin reuptake inhibitors (SSRIs)

Pharmacokinetics

Absorption: Fluoxetine is well absorbed following oral administration, with peak plasma concentrations typically reached within 6 to 8 hours for immediate-release formulations, and approximately 6 to 8 hours for delayed-release capsules. The absolute bioavailability is estimated to be around 72%. Absorption is not significantly affected by food intake, enabling administration without regard to meals. The medication exhibits a long half-life, supporting once-daily dosing and weekly dosing options in delayed-release forms.

Distribution: Fluoxetine is extensively distributed throughout body tissues with a volume of distribution approximately 20-40 L/kg, indicating wide tissue distribution. It binds extensively to plasma proteins, predominantly albumin, with binding levels around 94.5%. The drug is able to cross the blood-brain barrier efficiently, thereby exerting its therapeutic effects centrally. Furthermore, fluoxetine and its active metabolite can accumulate with repeated dosing due to their prolonged elimination half-lives.

Metabolism: Fluoxetine undergoes extensive hepatic metabolism primarily via cytochrome P450 isoenzymes, especially CYP2D6, to form its major active metabolite norfluoxetine. Norfluoxetine possesses similar pharmacological actions and a half-life even longer than the parent compound. The formation of norfluoxetine is essential for the prolonged duration of action observed with fluoxetine. Genetic polymorphisms in CYP2D6 can affect metabolism rates, impacting plasma levels and clinical response.

Elimination: The elimination half-life of fluoxetine is approximately 1 to 4 days after a single dose, extending to 4 to 6 days after chronic administration due to accumulation. Norfluoxetine has an even longer half-life of 4 to 16 days. The drug and its metabolites are primarily excreted renally, with approximately 60% eliminated in urine and the rest via feces. The slow elimination contributes to the drug's sustained pharmacodynamic effects and necessitates gradual dose adjustments. Clinically, the long half-life reduces the risk of withdrawal symptoms but requires consideration when switching antidepressants or discontinuing therapy.

Dosage Forms

Available Dosage Forms:
- Oral Capsules: 10 mg, 20 mg, 40 mg
- Delayed-Release Oral Capsules: 90 mg (for once-weekly dosing)
- Oral Solution: 20 mg/5 mL

Dosages for Adults and Adolescents:
- Major Depressive Disorder (MDD): Immediate-release capsules starting at 20 mg once daily in the morning, with maintenance doses of 20 to 60 mg daily, and a maximum dose of 80 mg daily. Delayed-release 90 mg capsule is administered once weekly following 7 days of daily dosing.
- Bulimia Nervosa: 60 mg orally once daily, may start at lower doses and titrate up.
- Obsessive-Compulsive Disorder (OCD): Starting at 20 mg daily, increased up to 60 mg daily. Maximum dose 80 mg daily.
- Panic Disorder: Initial dose 10 mg daily, increased to 20 mg after one week, maintenance 20-60 mg daily, maximum 60 mg daily.
- Premenstrual Dysphoric Disorder (PMDD): 20 mg daily continuously or cyclically starting 14 days before menses, maintenance 20-60 mg/day, maximum 80 mg/day.
- Pediatric Dosing for Depression (8-18 years): Initial 10-20 mg once daily, with maintenance 10-20 mg daily.
- Pediatric Dosing for OCD (7-17 years): Initial 10 mg daily increased to 20 mg; maintenance of 20-60 mg daily depending on weight and response.

Specific Patient Populations:
- Pediatric patients require careful dosing and monitoring with potential dose increases based on response and tolerability.
- Older adults may exhibit increased sensitivity; dose adjustments may be necessary.
- Patients with hepatic impairment require cautious dosing due to hepatic metabolism and longer half-life.
- Delayed-release weekly dosing capsules are beneficial for patients with adherence difficulties after initial daily dosing stabilization.

Clinical guidelines recommend gradual titration and caution with doses exceeding 60 mg daily due to limited safety data. Therapy duration varies by indication, commonly requiring several months for sustained remission.

Mechanism Of Action

Fluoxetine acts as a selective serotonin reuptake inhibitor (SSRI), exerting its therapeutic effects primarily by inhibiting the reuptake of serotonin (5-hydroxytryptamine, 5-HT) into presynaptic neuronal terminals. This inhibition increases the synaptic availability of serotonin in the central nervous system, thereby enhancing serotonergic neurotransmission. Elevated serotonin levels contribute to mood elevation, anxiolytic effects, and reduction in compulsive behaviors.

At the molecular level, fluoxetine binds with high affinity to the serotonin transporter (SERT), blocking serotonin reuptake without significant affinity for norepinephrine or dopamine transporters. This selective action distinguishes it from other antidepressants and reduces some side effects associated with non-selective agents. The increased serotonergic tone modulates downstream signaling pathways, including cyclic AMP and calcium-mediated signaling cascades, affecting neuronal plasticity and gene expression.

Fluoxetine’s active metabolite norfluoxetine also shares this mechanism, contributing to prolonged pharmacological activity. The combined presence of fluoxetine and norfluoxetine in plasma leads to sustained serotonin reuptake inhibition even with once-weekly dosing regimens.

Clinically, the mechanism results in alleviation of major depressive disorder, OCD, panic disorder, bulimia nervosa, and PMDD symptoms. Fluoxetine’s action contrasts with tricyclic antidepressants that affect multiple neurotransmitter systems but presents improved tolerability and safety profiles. Research demonstrates fluoxetine’s efficacy correlates with enhanced serotonergic function in limbic brain regions implicated in mood and anxiety disorders, as supported by neuroimaging and receptor binding studies.

Pharmacological Actions

Selective inhibition of serotonin reuptake at presynaptic neuronal terminals
Increase of serotonergic neurotransmission in central nervous system synapses
Elevation of synaptic serotonin levels leading to mood enhancement
Reduction of anxiety and panic symptoms through serotonergic modulation
Suppression of obsessive and compulsive behaviors via serotonin pathways
Anorectic effects contributing to regulation of eating behaviors in bulimia nervosa
Modulation of neuroplasticity and downstream intracellular signaling cascades
Active metabolite norfluoxetine prolongs duration of action
Minimal effect on norepinephrine and dopamine reuptake, contributing to selective action
Delayed onset of therapeutic effect due to receptor adaptation and neural remodeling
Potential mild antagonistic effects on certain serotonin receptor subtypes, modulating effects
Pharmacodynamic interactions with other serotonergic agents may precipitate serotonin syndrome
Inhibition of CYP2D6 enzyme, affecting metabolism of other drugs
Impact on hypothalamic-pituitary-adrenal (HPA) axis regulation related to depression
Influence on sleep architecture through serotonergic modulation

Therapeutic Or Clinical Uses

Treatment of major depressive disorder (MDD) including acute and maintenance phases
Management of obsessive-compulsive disorder (OCD) in adults and pediatric patients
Treatment of panic disorder with or without agoraphobia
Therapy for bulimia nervosa to reduce binge-eating and vomiting episodes
Treatment of premenstrual dysphoric disorder (PMDD) with continuous or cyclic regimens
Adjunctive treatment in bipolar disorder with olanzapine for depressive episodes resistant to other therapies
Off-label uses may include anxiety disorders and certain off-label pediatric mood disorders under supervision
Improvement of mood and reduction in suicidal ideation in at-risk populations when monitored
Use in patients requiring once-weekly dosing to enhance adherence after stabilization
Management of symptoms associated with chronic mood and anxiety disorders
Reduction of symptoms related to excessive worry and compulsive behaviors
Potential use in behavioral disorders in veterinary medicine (e.g., separation anxiety in dogs)
Treatment of depressive symptoms during pregnancy after risk-benefit analysis
Long-term maintenance therapy to prevent relapse of depressive and obsessive-compulsive symptoms
Treatment tailored to individual patient profiles considering tolerability and comorbidities

Side Or Adverse Effects

Insomnia and abnormal dreams including vivid or strange dreaming
Headache, dizziness, and somnolence or drowsiness
Tremors and increased nervousness or anxiety
Nausea, vomiting, diarrhea, and gastrointestinal upset
Dry mouth and excessive sweating (hyperhidrosis)
Sexual dysfunction including decreased libido, impotence, and anorgasmia
Weight changes, either gain or loss
Sinusitis, nasal congestion, and upper respiratory tract symptoms
Fatigue and generalized weakness or pain
Blurred vision, tunnel vision, and visual disturbances
Potential development of serotonin syndrome characterized by agitation, hallucinations, hyperthermia, muscle rigidity, and autonomic instability
Hyponatremia leading to symptoms like headache, confusion, vomiting, and coordination loss
Rare but serious allergic reactions including urticaria, angioedema, and severe skin reactions
Emotional instability manifesting as increased depression, suicidal thoughts particularly in young patients during early therapy
Caution with bleeding disorders as fluoxetine may impair platelet aggregation leading to bruising or bleeding

Precautions

Avoid concurrent use with monoamine oxidase inhibitors (MAOIs); allow at least 14 days washout period
Exercise caution in patients with history of bipolar disorder due to risk of inducing mania
Monitor closely patients with seizure disorders as fluoxetine may lower seizure threshold
Use with caution in patients with hepatic impairment due to extensive metabolism by liver enzymes
Assess risk-benefit in pediatric and adolescent patients due to increased risk of suicidal ideation
Careful monitoring for serotonin syndrome symptoms when co-administered with other serotonergic agents
Avoid abrupt discontinuation to prevent withdrawal symptoms; dose tapering recommended
Patients should be warned about potential impairment in judgment and motor skills
Evaluate for history of bleeding disorders or concomitant use of anticoagulants or NSAIDs
Pregnancy use requires careful consideration of maternal benefits versus potential fetal risks
Adjust dose or monitor therapeutic drug levels when used with drugs affecting CYP2D6 metabolism
Advise patients about alcohol use as it may amplify central nervous system side effects
Monitor sodium levels especially in elderly or patients on diuretics to detect hyponatremia early
Patients with narrow-angle glaucoma should be carefully assessed prior to starting therapy
Advise patients regarding potential sexual side effects and availability of management options

Warnings

Do not use concomitantly with thioridazine, pimozide, or methylene blue injection due to risk of serious interactions
Avoid use within 14 days of stopping MAO inhibitors; delay initiation of MAOI for 5 weeks after fluoxetine discontinuation
Black box warning for increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults
Risk of serotonin syndrome particularly when taken with other serotonergic medications or drugs
May impair ability to drive or operate machinery; caution advised until patient response is established
Report mood changes including agitation, hostility, or worsening depression promptly to healthcare provider
Serious cardiac arrhythmias and QT prolongation may be precipitated especially in predisposed individuals
Risk of severe hyponatremia and syndrome of inappropriate antidiuretic hormone secretion (SIADH)
Potential for severe skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis
Discontinue if signs of allergic reaction or severe rash occur
Use with caution in patients with history of mania or hypomania due to potential exacerbation
May increase bleeding risk, particularly when used with NSAIDs, aspirin, or anticoagulants
Patients should not abruptly discontinue medication to avoid withdrawal effects
Risk of excessive sedation or confusion in elderly patients
Monitor closely during pregnancy due to possible neonatal complications associated with SSRI use

Contraindication

Known hypersensitivity to fluoxetine or any component of the formulation
Concurrent use with monoamine oxidase inhibitors (MAOIs) due to risk of serotonin syndrome
Use of thioridazine or pimozide concomitantly or within 5 weeks of fluoxetine discontinuation
Patients currently receiving methylene blue injection
History of hypersensitivity reactions to other selective serotonin reuptake inhibitors (relative contraindication)
Use in combination with linezolid or intravenous methylene blue due to interaction risks
Severe hepatic impairment where metabolism might be significantly compromised
Concurrent use with other serotonergic drugs without appropriate clinical justification
Known QT prolongation or ventricular arrhythmias associated with fluoxetine administration
Pediatric patients under appropriate indication age without robust clinical evaluation
Use in patients with recent cardiac events or unstable cardiac conditions without specialist advice
Concomitant use with other drugs having serious interaction leading to life-threatening conditions
Use in untreated narrow-angle glaucoma without ophthalmologic monitoring
Use during late pregnancy without risk-benefit analysis due to neonatal complications
Combination with drugs that prolong QT interval is contraindicated

Drug Interactions

Monoamine oxidase inhibitors (MAOIs): Risk of serotonin syndrome; contraindicated concurrently or within 14 days
Thioridazine and pimozide: Increased risk of cardiac arrhythmias; contraindicated within 5 weeks post fluoxetine
Methylene blue injection: Risk of serotonin syndrome; contraindicated
Other serotonergic drugs like triptans, tramadol, St. John's Wort, and other SSRIs/SNRIs increase serotonin syndrome risk
Warfarin and other anticoagulants: Increased bleeding risk due to platelet function interference; monitor coagulation parameters
Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, naproxen: Enhanced bleeding risk
Drugs metabolized by CYP2D6 (e.g., certain antipsychotics, beta blockers, antiarrhythmics): Fluoxetine inhibits CYP2D6 and may increase plasma levels
Lithium and tricyclic antidepressants: Increased serotonergic and central nervous system effects; monitor for toxicity
CYP3A4 substrates: May require dose adjustments when used with fluoxetine due to enzyme interactions
Opioid analgesics (e.g., fentanyl, tramadol): Increased risk of CNS depression and serotonin syndrome
Antiepileptics like carbamazepine and phenytoin may alter fluoxetine metabolism; monitoring recommended
Benzodiazepines and other CNS depressants: Enhanced sedation possible
Drugs affecting cardiac conduction such as antiarrhythmics may potentiate QT prolongation
Concomitant use with ADHD medications (e.g., methylphenidate, amphetamines) may increase adverse central nervous system effects
Use with diuretics may increase risk of hyponatremia

Preparations Of The Drug

Fluoxetine oral capsules: Available in 10 mg, 20 mg, 40 mg strengths for immediate-release dosing
Fluoxetine delayed-release oral capsules: 90 mg formulation for once-weekly dosing regimen
Fluoxetine oral solution: 20 mg per 5 mL concentration to aid dosing accuracy and patient compliance
Combination oral preparations with olanzapine (e.g., Symbyax) for treatment of bipolar depression
Brand-specific formulations include Prozac, Sarafem, Rapiflux, and Selfemra with distinct packaging and labeling
Prescription-only oral dosage forms with varied bioavailability characteristics suited for different indications
Dosing devices such as calibrated syringes provided with liquid formulations for precise measurement
Extended therapy kits available for maintenance treatment requiring patient education for adherence
Generic equivalents available in immediate and delayed-release oral forms
Storage requirements: room temperature, protected from moisture and heat to maintain stability
Patient information leaflets included with each preparation for guidance on use and precautions
Packaging options include blister packs, bottles, and weekly dispenser boxes for delayed-release capsules
Manufactured under rigorous quality control to ensure consistent pharmacokinetic profiles
Specialty pharmacy compounding available for patients with specific dosing or formulation needs
Labeling includes warnings about potential withdrawal symptoms and drug interaction risks